Christmann D
Onkologie. 1986 Aug;9 Suppl 1:11-2. doi: 10.1159/000216055.
Epirubicin was applied in combination with vincristine and cyclophosphamide (VEC) against metastatic cancer of the breast in 14 patients, against advanced cancer of the ovaries. Epirubicin was applied in combination with cisplatin and cyclophosphamide (PEC) in 12 patients. Treatment of metastatic cancer of the breast achieved retrogression in 64%, the tumor was brought to a standstill in 12%. Treatment of cancer of the ovaries achieved complete retrogression in 75%, the tumor was brought to a standstill in 8.3%. There was no incidence of considerable myelo- or cardiotoxic side effects resulting in a necessary interruption of treatment. The achieved results of this treatment correspond to those with doxorubicin combinations, the toxicity, however, is less.
表柔比星与长春新碱和环磷酰胺（VEC）联合应用于14例转移性乳腺癌患者以及晚期卵巢癌患者。表柔比星与顺铂和环磷酰胺（PEC）联合应用于12例患者。转移性乳腺癌的治疗使64%的患者病情消退，12%的患者肿瘤停止发展。卵巢癌的治疗使75%的患者完全消退，8.3%的患者肿瘤停止发展。未出现导致治疗必须中断的严重骨髓或心脏毒性副作用。该治疗所取得的结果与阿霉素联合治疗的结果相当，然而毒性较小。
